BlossomHill Therapeutics, Inc. BLSM
- Market cap
- $650.6M
- P/E
- —
Follow BLSM
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | — | 63 |
Employees
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | 0 |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
BlossomHill Therapeutics, Inc. (BLSM) Latest News
18 Sep
BlossomHill Therapeutics, Inc. (BLSM) reported its second quarter 2026 financial results. Quarterly financial results deliver performance metrics that can shift near-term investor views and trading activity.
15 Sep
BlossomHill Therapeutics shares rose 4.4% following an update on the BH-30643 trial. BH-30643 trial update produced a 4.4% share price gain that signals material investor response to clinical progress.
BlossomHill Therapeutics presented updated Phase 1/2 SOLARA trial data demonstrating encouraging anti-tumor activity of OMNI-EGFR inhibitor BH-30643 in EGFR C797S-positive NSCLC at IASLC 2026 World Conference on Lung Cancer. Positive clinical data on lead asset BH-30643 in targeted NSCLC population boosts pipeline value and market positioning.
1 Sep
BlossomHill Therapeutics will present updated data from its ongoing Phase 1/2 SOLARA trial of BH-30643 in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer. Conference presentation of Phase 1/2 trial updates may affect near-term sentiment around clinical progress in NSCLC.
18 Aug
BlossomHill Therapeutics receives FDA Fast Track Designation for BH-30643, a macrocyclic OMNI-EGFR inhibitor, for treatment of advanced EGFR C797S-positive NSCLC. Fast Track Designation accelerates regulatory review and development timeline for lead oncology asset BH-30643.
6 Aug
BlossomHill Therapeutics priced its upsized initial public offering at $150 million. The upsized $150 million IPO delivers major capital infusion and shifts the company to public markets, substantially altering its financial trajectory and investor base.